evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,149 questions · 1,211 findings · 179 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 175 · 14.5%GRADE not reported 86 · 7.1%Very low 286 · 23.6%Low 341 · 28.2%Moderate 254 · 21%High 69 · 5.7%

Intervention not reported

Quality of life ‐ intermediateMSIS, MSQOL, SF‐36, SF‐12, SWLS, EQ‐5D‐5La · people with multiple sclerosis
1 finding from 1 review

Intervention not reported

Acitivities of daily living ‐ intermediateEADLa · people with multiple sclerosis
1 finding from 1 review

Siponimod vs placebo

Relapse · people with multiple sclerosis

It is very uncertain whether siponimod changes number of participants with relapses at 6 months compared with placebo (very low certainty).

1 finding from 1 review

Siponimod vs placebo

Disability worsening · people with multiple sclerosis

Siponimod may leads to lower participants with disability worsening at 6 months compared with placebo (low certainty).

1 finding from 1 review

Siponimod vs placebo

Withdrawals due to adverse events · people with multiple sclerosis

Siponimod showed no clear difference in number of participants who withdrew due to AEs at 6 months compared with placebo (low certainty).

1 finding from 1 review

Siponimod vs placebo

Annualised relapse rate · people with multiple sclerosis

Siponimod may leads to lower annualised relapse rate compared with placebo (low certainty).

1 finding from 1 review

Siponimod vs placebo

Mean number of gadolinium‐enhancing lesions on T1‐weighted brain MRI image at 6 months · people with multiple sclerosis

It is very uncertain whether siponimod changes mean number of gadolinium‐enhancing lesions on T1‐weighted brain MRI… compared with placebo (very low certainty).

1 finding from 1 review

Siponimod vs placebo

Mean number of new lesions or enlarged pre‐existing lesions on T2‐weighted brain MRI images at 6 months · people with multiple sclerosis

Siponimod may leads to lower mean number of new lesions or enlarged pre‐existing lesions on… compared with placebo (low certainty).

1 finding from 1 review

Siponimod vs placebo

SAEs · people with multiple sclerosis

Siponimod showed no clear difference in number of participants with at least one SAE at 6 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Common infections measured by clinical assessment over 28 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in common infections measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Cancer · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in cancer measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Mortality measured by clinical assessment over 12 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in mortality measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Clinical relapse · relapsing multiple sclerosis

Rituximab as 'switching' may leads to lower relapse measured by clinical assessment over 12 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Serious adverse events measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Common infections measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Cancer · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review